Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus

• by Shaoqin Yang, Shuangshuang Zhang, Yuming Gu

• June 15, 2026

Predicting CAR-T outcomes in R/R DLBCL: a multicenter real-world study of a 5-index model

• by Bin Xue, Huina Lu, Yifan Liu, Ying Lu, Wenjun Zhang, Bing Xiu, Xiu Luo, Li Wang, Wenbin Qian, Aibin Liang, Ping Li

• June 16, 2026

A nomogram as a predictive tool for lymph node metastasis in papillary thyroid carcinoma

• by Yimeng Liu, Tianxiang Liu, Yi Long, Xin Wang, Mei Tao, Kejia Xu, Xing Wan, Jimin Zhao, Guangwei Xu, Jie Gao, Yongjun Piao, Xuan Qin, Xiangqian Zheng

• June 16, 2026

Parabilis Sets Biotech IPO Record

The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement

• June 15, 2026

• 2 min